1. Volume 3, Issue 1, Pages 1-9 (January 2017)
Tolerability of ORM and effects on episodic memory in patients with Alzheimer's disease 
Juha O. Rinne, Keith Wesnes, Jeffrey L. Cummings, Pasi Hakulinen, Merja Hallikainen, Jutta Hänninen, Michael Murphy, Henry Riordan, Mika Scheinin, Hilkka Soininen, Juha Rouru 
Alzheimer's & Dementia: Translational Research & Clinical Interventions 
Volume 3, Issue 1, Pages 1-9 (January 2017)
DOI: /j.trci
Copyright © 2016 Orion Pharma Terms and Conditions

2. Fig. 1 Disposition of subjects.
Alzheimer's & Dementia: Translational Research & Clinical Interventions 2017 3, 1-9DOI: ( /j.trci )
Copyright © 2016 Orion Pharma Terms and Conditions

3. Fig. 2
Quality of Episodic Memory, Quality of Working Memory, and Quality of Memory CDR composite scores. Data are presented as LS means (SE) for changes from baseline. A positive change from baseline indicates improvement. *P < .05, **P < .01, ***P < .001 for difference versus placebo at time point. Abbreviations: CDR, Cognitive Drug Research; LS means, least squares means; SE, standard error.
Alzheimer's & Dementia: Translational Research & Clinical Interventions 2017 3, 1-9DOI: ( /j.trci )
Copyright © 2016 Orion Pharma Terms and Conditions

4. Fig. 3
NPI total and NPI caregiver distress scores. Data are presented as LS means (SE) for changes from baseline. A negative change from baseline indicates improvement. *P < .05, **P < .01 for difference versus placebo at time point. Abbreviations: LS means, least squares means; NPI, Neuropsychiatric Inventory; SE, standard error.
Alzheimer's & Dementia: Translational Research & Clinical Interventions 2017 3, 1-9DOI: ( /j.trci )
Copyright © 2016 Orion Pharma Terms and Conditions